Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical study for efficacy and safety of Oncorine (Recombinant Human Adenovirus Type 5 Injection) combined with mFOLFOX6+ bevacizumab in the treatment of unresectable colorectal adenocarcinoma with liver metastases

Next Previous
Trial Profile

Clinical study for efficacy and safety of Oncorine (Recombinant Human Adenovirus Type 5 Injection) combined with mFOLFOX6+ bevacizumab in the treatment of unresectable colorectal adenocarcinoma with liver metastases

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs H-101 (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Liver metastases
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TROJAN 021

Most Recent Events

  • 04 Jun 2024 Results (n=21) assessing safety and efficacy of recombinant human adenovirus type 5 (H101) combined with immune checkpoint inhibitors (ICIs) in patients with liver metastatic gastric cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 08 Jun 2021 Results (n=8) assessing safety and efficacy of H101 treatment in patients with hepatic metastasis of colorectal cancer, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
  • 03 Feb 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top